Biblio
“Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Racial/Ethnic Disparities in Misidentification of Dementia in Medicare Claims: Results from the Washington Heights-Inwood Columbia Aging Project.”, J Alzheimers Dis, vol. 96, no. 1, pp. 359-368, 2023.
, “Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes.”, J Alzheimers Dis, vol. 96, no. 1, pp. 47-56, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Reliability and Validity of Self-Reported Vascular Risk Factors: Hypertension, Diabetes, and Heart Disease, in a Multi-Ethnic Community Based Study of Aging and Dementia.”, J Alzheimers Dis, vol. 95, no. 1, pp. 275-285, 2023.
, “A Remotely Coached Multimodal Lifestyle Intervention for Alzheimer's Disease Ameliorates Functional and Cognitive Outcomes.”, J Alzheimers Dis, vol. 96, no. 2, pp. 591-607, 2023.
, “Resveratrol Mediated Regulation of Hippocampal Neuroregenerative Plasticity via SIRT1 Pathway in Synergy with Wnt Signaling: Neurotherapeutic Implications to Mitigate Memory Loss in Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S125-S140, 2023.
, “Retinal Functional and Structural Neural Indices: Potential Biomarkers for the Monitoring of Cerebral Neurodegeneration: The Maastricht Study.”, J Alzheimers Dis, vol. 93, no. 4, pp. 1471-1483, 2023.
, “Rheumatoid Arthritis and Cognitive Impairment or Dementia: An Updated Review of Epidemiological Data.”, J Alzheimers Dis, vol. 95, no. 3, pp. 769-783, 2023.
, “Risk Factors for Longer-Term Mortality in Discharged Patients with Dementia and SARS-CoV-2 Infection: A Matched Case-Control Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 295-309, 2023.
, “The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.”, J Alzheimers Dis, vol. 94, no. s1, pp. S45-S66, 2023.
, “S1PR2 Regulates Autophagy Through the AKT/mTOR Pathway to Promote Pathological Damage in Alzheimer's Disease.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1489-1504, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Senescent Microglia Represent a Subset of Disease-Associated Microglia in P301S Mice.”, J Alzheimers Dis, vol. 95, no. 2, pp. 493-507, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “Superior Global Cognition in Oldest-Old Is Associated with Resistance to Neurodegenerative Pathologies: Results from The 90+ Study.”, J Alzheimers Dis, vol. 93, no. 2, pp. 561-575., 2023.
, “Tau Loss of Function, by Deletion or Aggregation, Contributes to Peripheral Insulin Resistance.”, J Alzheimers Dis, vol. 95, no. 3, pp. 1041-1058, 2023.
, “TDP-43 Pathology in the Setting of Intermediate and High Alzheimer's Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups.”, J Alzheimers Dis, vol. 91, no. 4, pp. 1291-1301, 2023.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Two-Year Changes in Physical Activity and Concurrent Changes in Cognitive Function in a Cohort of Adults with Metabolic Syndrome.”, J Alzheimers Dis, vol. 95, no. 3, pp. 887-899, 2023.
, “Type 2 Diabetes Comorbidity and Cognitive Decline in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 4, pp. 1573-1584, 2023.
, “Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S187-S202, 2023.
, “Unlocking Modifiable Risk Factors for Alzheimer's Disease: Does the Oral Microbiome Hold Some of the Keys?”, J Alzheimers Dis, vol. 92, no. 4, pp. 1111-1129, 2023.
, “Untangling the Role of TREM2 in Conjugation with Microglia in Neuronal Dysfunction: A Hypothesis on a Novel Pathway in the Pathophysiology of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S319-S333, 2023.
,